Abstract: A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).
Abstract: Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.
Type:
Grant
Filed:
July 30, 2004
Date of Patent:
March 31, 2009
Assignee:
Genelabs Technologies, Inc.
Inventors:
Franz Ulrich Schmitz, Christopher Don Roberts, Ronald Conrad Griffith, Janos Botyanszki, Mikail Hakan Gezginci, Joshua Michael Gralapp, Dong-Fang Shi, Sebastian Johannes Reinhard Liehr
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein W, W1, W2, Y, R1, Z, Y? and R are as defined herein.
Type:
Grant
Filed:
July 24, 2006
Date of Patent:
October 7, 2008
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher D. Roberts, Jesse Keicher, Natalia B. Dyatkina
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula IB as follows: and pharmaceutically acceptable prodrugs and salts thereof, where R, R1, R13, R14, W, W2, W3, Y and Z are as defined herein.
Type:
Grant
Filed:
September 30, 2003
Date of Patent:
September 16, 2008
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher Don Roberts, Natalia B. Dyatkina
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.
Type:
Grant
Filed:
November 15, 2005
Date of Patent:
August 19, 2008
Assignee:
Genelabs Technologies, Inc.
Inventors:
Jesse D. Keicher, Christopher D. Roberts, Natalia B. Dyatkina
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus.
Type:
Grant
Filed:
April 25, 2006
Date of Patent:
July 29, 2008
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher D. Roberts, Ronald Conrad Griffith, Natalia B. Dyatkina, Marija Prhavc
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, T, Y, W, W1 and W2 are as defined herein.
Type:
Grant
Filed:
October 21, 2004
Date of Patent:
July 17, 2007
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher D. Roberts, Jesse D. Keicher, Natalia B. Dyatkina
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, each of R, Y, W, W1 and W2 are as defined herein.
Type:
Grant
Filed:
June 4, 2004
Date of Patent:
April 10, 2007
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher D. Roberts, Jesse D. Keicher
Abstract: The present invention provides molecular switch system methods and compositions for use in regulatable gene expression. The system includes a nucleic acid construct which has a DNA response sequence for a transcriptional regulatory protein operably linked to a promoter, a compound binding sequence in the vicinity of the DNA response sequence, a transgene under the control of the promoter; and a DNA binding compound. In some cases, the molecular switch system further includes a nucleic acid sequence encoding a transcriptional regulatory protein operably linked to a second promoter. The invention further provides a method for screening compounds for the ability to function in the molecular switch system and thereby regulate gene expression.
Type:
Grant
Filed:
March 3, 2000
Date of Patent:
March 13, 2007
Assignee:
Genelabs Technologies, Inc.
Inventors:
Moon Young Lim, Cynthia A. Edwards, Kirk E. Fry, Thomas W. Bruice, Douglas B. Starr, Megan E. Laurance, Yan Kwok, Albert W. Tam
Abstract: Disclosed are methods and intermediates for the preparation of 7-(2?-R1-substituted-?-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds. These compounds are useful in treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such 7-(2?-substituted-?-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds are represented by Formula I as follows: wherein, each of R1, R2, and R3 are as defined herein.
Type:
Grant
Filed:
October 20, 2004
Date of Patent:
January 30, 2007
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher D. Roberts, Jesse D. Keicher, Natalia B. Dyatkina
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, Y, W, W1 and W2 are as defined herein.
Type:
Grant
Filed:
October 20, 2004
Date of Patent:
January 2, 2007
Assignee:
Genelabs Technologies, Inc.
Inventors:
Jesse D. Keicher, Christopher D. Roberts, Natalia B. Dyatkina
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, R, Y, W, W1 and W2 are as defined herein.
Type:
Grant
Filed:
June 4, 2004
Date of Patent:
December 19, 2006
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher D. Roberts, Jesse D. Keicher
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, each of R, Y, W, W1 and W2 is as defined herein.
Type:
Grant
Filed:
June 4, 2004
Date of Patent:
December 5, 2006
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher D. Roberts, Jesse D. Keicher
Abstract: The present invention provides novel compounds possessing antibacterial, and/or antifungal activities. Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.
Type:
Grant
Filed:
September 18, 2003
Date of Patent:
November 28, 2006
Assignee:
Genelabs Technologies, Inc.
Inventors:
Janos Botyanszki, Dong-Fang Shi, Christopher Don Roberts, Mikail Hakan Gezginci, Stephen Corey Valdez, Sherwin Sattarzadeh
Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.
Type:
Grant
Filed:
May 7, 2001
Date of Patent:
August 22, 2006
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services and Genelabs Technologies, Inc.
Inventors:
Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert W. Tam, Kirk E. Fry
Abstract: Disclosed are 6-hydroxyamino- or a 6-alkoxyamino-7-deazapurine-ribofuranose derivatives, salts, pharmaceutical compositions, and methods of use thereof for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.
Type:
Grant
Filed:
April 8, 2004
Date of Patent:
August 22, 2006
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher D. Roberts, Jesse Keicher, Natalia B. Dyatkina
Abstract: The present invention provides novel compounds possessing one or more of the following activities: antibacterial, antifungal and antitumor activity. The compounds are of Formula (I): Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.
Type:
Grant
Filed:
December 24, 2002
Date of Patent:
June 20, 2006
Assignee:
Genelabs Technologies, Inc.
Inventors:
Natalia B. Dyatkina, Dong-Fang Shi, Christopher Don Roberts, Mark Douglas Velligan, Sebastian Johannes Reinhard Liehr, Janos Botyanszki, Wentao Zhang, Alexander Khorlin, Peter Harold Nelson, Joseph Martin Muchowski
Abstract: Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at least one pharmaceutical excipient. Methods for making and using such compositions are also disclosed.
Type:
Grant
Filed:
March 16, 2000
Date of Patent:
May 16, 2006
Assignee:
Genelabs Technologies, Inc.
Inventors:
Jagdish Parasrampuria, Maxine B. Yonker, Kenneth E. Schwartz, Marc J. Gurwith
Abstract: This invention provides novel compounds possessing antibacterial and/or antifungal and/or antitumor activity. Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.
Type:
Grant
Filed:
May 15, 2003
Date of Patent:
October 4, 2005
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christoher Don Roberts, Jesse Daniel Keicher, Mikail Hakan Gezginci, Mark Douglas Velligan